
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Michael J. Morris, MD, GU Oncologists, Memorial Sloan Kettering Cancer Center, discusses the results of the ECOG E3805 study, which examined chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer.
Michael J. Morris, MD, GU Oncologists, Memorial Sloan Kettering Cancer Center, discusses the results of the ECOG E3805 study, which examined chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer.
Clinical Pearls:
<<<






